HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Brands Invests $111m To Boost Advertising From Market Research

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

Prestige Brands supports leading brands including Monistat and Dramamine with promotional campaigns stemming from research into consumer preferences, says sales and marketing head Timothy Connors. With $111m ad spend, it aims to become a “preeminent marketing and sales” firm.

You may also be interested in...



Prestige Consumer Healthcare Grows Global View

Overall revenues up 2.6% for October-December to $282.7m as, for second consecutive quarter, PCH reported international sales driving growth. International grew nearly 20% to $46.2m, while North America sales were down for second straight period.

Prestige Consumer Not Thirsty For Bringing International Sales Leader Hydralyte To US

Expanding Hydralyte sales to US sports beverage market might seem a likely target for PCH. But firm doesn’t plan to bring its Hydralyte products to the US, where a smaller company owns and markets the brand.

Prestige Consumer Expects 4% Sales Dip For Its FY2021 As COVID-19 Clouds Economic Forecast

North American sales for the consumer health segment in the quarter reached $216.6m core products on women’s health, analgesics, oral care and ear and eye care categories, partially offset by declines in cough and cold products as well as gastrointestinal products.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel